# Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

Study · id `cardio:ct-nct02960126` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02960126](<https://clinicaltrials.gov/study/NCT02960126>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02960126

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT02960126. Randomized; no masking; primary purpose treatment. Start 2016-11 (registry gives no type); primary completion 2020-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT02960126, source copy `cardio:ctgov-nct02960126-2016-11-09`, retrieved 2026-10-26)
- Start date: 2016-11 (registry gives no type) (ClinicalTrials.gov record NCT02960126, source copy `cardio:ctgov-nct02960126-2016-11-09`, retrieved 2026-10-26)
- Primary completion: 2020-10 (anticipated) (ClinicalTrials.gov record NCT02960126, source copy `cardio:ctgov-nct02960126-2016-11-09`, retrieved 2026-10-26)
- Completion: 2021-10 (anticipated) (ClinicalTrials.gov record NCT02960126, source copy `cardio:ctgov-nct02960126-2016-11-09`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02960126-2016-11-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk
- Acronym: CESAC-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Lead sponsor: Chuncheon Sacred Heart Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)

## Provenance

Content hash: 1596664a8206eda2dde133bc839401567c1244febbe49084ae295ac973b1a4be
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
